Welcome to our dedicated page for Oragenics news (Ticker: OGEN), a resource for investors and traders seeking the latest updates and insights on Oragenics stock.
Oragenics, Inc. (NYSE American: OGEN) is a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology. News related to Oragenics often centers on the progress of its lead intranasal drug candidate, ONP-002, which is being advanced for the treatment of concussion and mild traumatic brain injury, as well as broader developments in its intranasal platform for neurological disorders.
Investors and followers of OGEN can use this news feed to track company announcements about clinical milestones, such as Human Research Ethics Committee approval in Australia, selection of Southern Star Research as Clinical Research Organization for the Phase IIa ONP-002 trial, and updates on anticipated Phase IIa and Phase IIb studies. Oragenics’ press releases also cover manufacturing and operational agreements, including its cGMP production partnership with Sterling Pharma Solutions to supply ONP-002 for clinical development.
Another recurring theme in Oragenics news is strategic and financial activity. The company has reported public offerings of Series H Convertible Preferred Stock and Warrants, at-the-market equity sales, and related steps taken to restore and maintain compliance with NYSE American stockholders’ equity requirements. These updates provide context on how Oragenics is funding its clinical programs and strengthening its balance sheet.
In addition, Oragenics issues news about pipeline expansion and partnerships, including its collaboration with Receptor.AI, an artificial intelligence–driven drug profiling company, aimed at accelerating development of additional pharmaceutical candidates for brain health. The company also announces its participation in industry conferences and investor events, where it presents its intranasal concussion program and broader neurological platform. Readers interested in OGEN can follow this page for ongoing disclosures directly sourced from company press releases and related regulatory communications.
Oragenics, Inc. (NYSE American: OGEN) has entered into a material transfer agreement with Biodextris Inc. regarding the use of three intranasal mucosal adjuvants for its Terra CoV-2 vaccine against COVID-19. The adjuvants—BDX100, BDX300, and BDX301—aim to enhance immune response and manufacturing efficiency. This collaboration will facilitate preclinical studies essential for FDA Investigational New Drug applications and potential clinical trials. Oragenics' vaccine offers advantages like refrigerated storage, aiming to address ongoing COVID-19 vaccination needs.
Oragenics, Inc. (NYSE American: OGEN) announced that its CEO, Alan Joslyn, Ph.D., will participate in two virtual investment conferences in March 2021. The events are the H.C. Wainwright Global Life Sciences Virtual Conference on March 9-10 and the Roth Conference on March 15-17. A prerecorded presentation for the Roth Conference will be available on the Company's website starting March 9. Oragenics focuses on developing a vaccine for COVID-19 and novel antibiotics, leveraging research from the National Institutes of Health.
Oragenics, Inc. (NYSE American: OGEN) announced a successful capital raise of approximately $20 million through a sales agreement with A.G.P./Alliance Global Partners. The firm also gained around $1.9 million from exercising common stock warrants. Furthermore, Oragenics will redeem all shares of its Series C Preferred Stock, valued at $5.6 million, which eliminates a 20% preferred dividend. These funds will support the Phase 2 clinical trial of its SARS CoV-2 vaccine, Terra CoV-2, and advance its lantibiotics program.
Oragenics, Inc. (NYSE American: OGEN) has announced positive results for its COVID-19 vaccine candidate, Terra CoV-2. Research from the NIH indicates that the spike protein S-2P, licensed by Oragenics, induced protective immunity in mice infected with SARS-CoV-2. The study showed complete inhibition of virus growth in treated mice, with significant immune responses measured. The results support the ongoing development of Terra CoV-2, a candidate positioned to address the estimated 12-14 billion doses needed globally for COVID-19 vaccination. The company aims to file an Investigational New Drug application soon.
Oragenics, Inc. (NYSE American: OGEN) issued a letter to stockholders from CEO Alan Joslyn, updating on the COVID-19 vaccine Terra CoV-2. The firm has gained confidence from recent vaccine developments and has a nonexclusive license from the NIH for a prefusion stabilized spike protein vaccine candidate. Oragenics held a pre-IND meeting with the FDA, streamlining its timelines. The company raised $12.5 million in recent financing, aiming to advance vaccine studies. Despite financial hurdles, Oragenics believes in market demand for multiple vaccines against COVID-19.
Oragenics, Inc. (NYSE American: OGEN) announced a material transfer agreement with Adjuvance Technologies for the use of the adjuvant TQL1055 in its Terra CoV-2 vaccine against COVID-19. TQL1055 is designed to enhance immunogenicity, with initial studies planned to support the FDA Investigational New Drug application in Q1 2021. The vaccine aims for a robust immune response with lower antigen doses, and will be assessed in various animal studies. The vaccine's stable storage conditions may improve distribution.
Oragenics, Inc. (NYSE American: OGEN) has successfully closed its registered direct offering of 14,444,444 shares of common stock at $0.45 per share, raising gross proceeds of $6.5 million. The funds will primarily support the pre-clinical development of its Terra CoV-2 vaccine candidate, aimed at combating the coronavirus, as well as its lantibiotics program and general corporate initiatives. The shares were offered under a previously effective registration statement with the SEC.
Oragenics, Inc. (NYSE American: OGEN) has announced a registered direct offering of 14,444,444 shares of common stock at $0.45 per share, with closing expected on December 29, 2020. This offering is underpinned by an effective shelf registration statement filed with the SEC. A.G.P./Alliance Global Partners is the sole placement agent. The company is focused on developing the Terra CoV-2 vaccine candidate against COVID-19, leveraging NIH research. Investors are advised to review the forthcoming prospectus supplement for detailed information regarding the offering.